clinical trial · NCT05233033
Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL
Non Hodgkin LymphomaDiffuse Large B Cell LymphomaDLBCLMYD88 Gene MutationKT-413
brief summary
This Phase 1a/1b study will evaluate the safety, tolerability and the pharmacokinetics/ pharmacodynamics (PK/ PD) of KT-413 in patients with R/R NHL. The Phase 1a stage of the study will explore escalating doses of single-agent KT-413. The Phase 1b stage will be split into 2 expansion cohorts to further characterize the safety, tolerability and the pharmacokinetics/ pharmacodynamics (PK/ PD) of KT-413 in MYD88 mutant and MYD88 wild-type R/R DLBCL.
started
Jun 13, 2022
primary completion
Jul 28, 2023
completion
Jul 28, 2023
last updated
Dec 10, 2024
official title
A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, PK/PD, and Clinical Activity of Intravenously Administered KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol